Among the LUAD-like cases, T-SCLC patients treated with EGFR-TKI/bevacizumab plus chemotherapy showed a higher response (ORR 71.4%, mPFS 6.2 months) compared to those who received other treatments (ORR 40%, mPFS 2.7 months) (Fig. 6A). Here, EGFR is linked to small cell lung carcinoma.